Allena Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Allena Pharmaceuticals has a total shareholder equity of $3.7M and total debt of $4.9M, which brings its debt-to-equity ratio to 131.1%. Its total assets and total liabilities are $17.8M and $14.1M respectively.
Key information
131.1%
Debt to equity ratio
US$4.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.59m |
| Equity | US$3.74m |
| Total liabilities | US$14.07m |
| Total assets | US$17.81m |
Recent financial health updates
Recent updates
First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment
Jul 19Allena Pharma reschedules special meeting to approve reverse stock split, shares fall
Jul 05Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days
Jan 08Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?
Dec 29
Allena Pharmaceuticals announces $10M bought deal
Dec 01Allena Pharma's ALLN-346 shows encouraging action in early-stage study
Nov 30Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow
Nov 11Allena Pharmaceuticals EPS misses by $0.01
Nov 09Financial Position Analysis
Short Term Liabilities: ALNA.Q's short term assets ($16.5M) exceed its short term liabilities ($10.4M).
Long Term Liabilities: ALNA.Q's short term assets ($16.5M) exceed its long term liabilities ($3.6M).
Debt to Equity History and Analysis
Debt Level: ALNA.Q has more cash than its total debt.
Reducing Debt: ALNA.Q's debt to equity ratio has increased from 36.6% to 131.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALNA.Q has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALNA.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.